Abstract:Myocardial infarction (MI) is a life-threatening disease resulting from irreversible death of cardiomyocytes (CMs) and weakening of the heart blood-pumping function. Stem cell-based therapies have been studied for MI treatment over the last two decades with promising outcome. In this review, we critically summarize the past work in this field to elucidate the advantages and disadvantages of treating MI using pluripotent stem cells (PSCs) including both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), adult stem cells, and cardiac progenitor cells. The main advantage of the latter is their cytokine production capability to modulate immune responses and control the progression of healing. However, human adult stem cells have very limited (if not 'no') capacity to differentiate into functional CMs in vitro or in vivo. In contrast, PSCs can be differentiated into functional CMs although the protocols for the cardiac differentiation of PSCs are mainly for adherent cells under 2D culture. Derivation of PSC-CMs in 3D, allowing for large-scale production of CMs via modulation of the Wnt/β-catenin signal pathway with defined chemicals and medium, may be desired for clinical translation. Furthermore, the technology of purification and maturation of the PSC-CMs may need further improvements to eliminate teratoma formation after in vivo implantation of the PSC-CMs for treating MI. In addition, in vitro derived PSC-CMs may have mechanical and electrical mismatch with the patient's cardiac tissue, which causes arrhythmia. This supports the use of PSC-derived cells committed to cardiac lineage without beating for implantation to treat MI. In this case, the PSC derived cells may utilize the mechanical, electrical, and chemical cues in the heart to further differentiate into mature/functional CMs in situ. Another major challenge facing stem cell therapy of MI is the low retention/survival of stem cells or their derivatives (e.g., PSC-CMs) in the heart for MI treatment after injection in vivo. This may be resolved by using biomaterials to engineer stem cells for reduced immunogenicity, immobilization of the cells in the heart, and increased integration with the host cardiac tissue. Biomaterials have also been applied in the derivation of CMs in vitro to increase the efficiency and maturation of differentiation. Collectively, a lot has been learned from the past failure of simply injecting intact stem cells or their derivatives in vivo for treating MI, and bioengineering stem cells with biomaterials is expected to be a valuable strategy for advancing stem cell therapy towards its widespread application for treating MI in the clinic.

Therapeutic effects of CXCR4 + subpopulation of transgene‐free induced cardiosphere‐derived cells on experimental myocardial infarction

SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction.

Exosomes/microvesicles from Induced Pluripotent Stem Cells Deliver Cardioprotective Mirnas and Prevent Cardiomyocyte Apoptosis in the Ischemic Myocardium

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

Abstract 19996: Cardiac Mesenchymal Stem Cells with High Endogenous Gata4 Promoter Activity Have Superior Capacity to Elicit Cardiac Repair

Concise Review: Optimized Strategies for Stem Cell-based Therapy in Myocardial Repair: Clinical Translatability and Potential Limitation.

Abstract 17048: Exosomes from Induced Pluripotent Stem Cells Deliver Cardioprotective Mirnas and Prevent Cardiomyocyte Apoptosis in the Ischemic Myocardium

MENSTRUAL BLOOD STEM CELLS IMPROVED MYOCARDIAL SURVIVAL AFTER RAT MYOCARDIAL INFARCTION BY PARACRINE

Menstrual Blood Stem Cells Rescue Myocardiocytes in Rat Myocardial Infarction by Regulating Redox and Decreasing ROS Generation Through Paracrine Action

Overexpression of Csx/Nkx2.5 and GATA-4 Enhances the Efficacy of Mesenchymal Stem Cell Transplantation after Myocardial Infarction

Stem Cell Therapy of Myocardial Infarction: A Promising Opportunity in Bioengineering

Abstract P1103: A Combinatorial Stem Cell Therapy Using HiPSC-derived Cardiomyocytes And HiPSC-derived Mesenchymal Stem Cells For Cardiac Regeneration

Genetically modified mesenchymal stromal cells: a cell-based therapy offering more efficient repair after myocardial infarction

[Effects of Marrow-Derived Cardiac Stem Cell Transplantation after Myocardial Infarction in Rats].

An acute immune response underlies the benefit of cardiac stem cell therapy

Cardioprotective microRNAs: Lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease

Direct in Vivo Reprogramming with Non-Viral Sequential Targeting Nanoparticles Promotes Cardiac Regeneration.

Study on Transplantation of Marrow-derived Cardiac Stem Cells Pretreated with Diazoxide for Treatment of Myocardial Infarction

Another possible cell source for cardiac regenerative medicine: reprogramming adult fibroblasts to cardiomyocytes and endothelial progenitor cells.

hESCs‐Derived Early Vascular Cell Spheroids for Cardiac Tissue Vascular Engineering and Myocardial Infarction Treatment

Abstract 15107: Comparative Therapeutic Efficacy and Mechanism of Stem Cells in Rat Myocardial Infarction Model